ClinicalTrials.gg
CompletedNCT06000410Updated Apr 21, 2026

A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

A Phase 3 interventional study of Amniotic Suspension Allograft and Placebo in Knee Osteoarthritis, sponsored by Organogenesis. Completed at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Organogenesis · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 2 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Apr 2026.
Phase
Phase 3
Study type
Interventional
Enrollment
594
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-13

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 153 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Enrollment
37th of 691
594 · median 72
Started
2023
with 46 others
Phase 3
76 of 796
6 open now
Registered
695th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 37th largest by enrollment of the 691 interventional ones that give a count, is one of 47 that started in 2023, is one of 76 in phase 3, and was the 695th registered.

Osteoarthritis, Knee

3,292 studies on the registry are indexed under Osteoarthritis, Knee; 621 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 382 Osteoarthritis, Knee studies recruiting now, 176 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Watch this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo in the management of osteoarthritis (OA) symptoms of the knee.

Read the detailed description

This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3 study of ASA in patients with OA of the knee. Initially, 474 subjects are planned for inclusion in this study using a group sequential design with an interim analyses and a final analysis. Patients will be randomly assigned in a 1:1 ratio to receive a single intra-articular (IA) injection of 2 mL of ASA (plus 2 mL of normal saline) or 4 mL of normal saline on Day 1.

They will have serial assessments of knee pain, function, and symptoms scores, as well as safety assessments for up to 52 weeks after administration of the study drug.

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Osteoarthritis
  • Knee
  • Arthritis
  • Joint Disease
  • Musculoskeletal Diseases
  • Rheumatic Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females 18 years of age or older
  • Diagnosis of OA of the index knee by a combination of clinical and radiographic findings.
  • OA of the index knee with Kellgren and Lawrence radiographic classification (Grades 2-4 inclusive),
  • Patients who have failed to adequately respond for at least 6 months to at least two osteoarthritis therapies within the last 12 months
  • Overall index knee pain score above minimum required WOMAC Pain scale.
  • \< 40 kg/m2
  • Using , sterile or .
  • Able to understand and provide written

Exclusion criteria

Exclusion Criteria:

  • Kellgren and Lawrence radiographic grade 1 OA of the knee
  • Use of pain medication less than 5 days before the baseline visit
  • Regular use of anticoagulants
  • Symptoms that could indicate meniscal displacement or an IA loose body.
  • injection into the index knee within 3 months prior to screening.
  • Viscosupplement or any other autologous or allogeneic product into the index knee within 6 months prior to screening.
  • Patients with known reactions to ASA or any of its constituents.
  • Knee surgery on the index knee within 12 months prior to screening and/or planned knee surgery during the study
  • Knee surgery on the contralateral knee within 6 months prior to screening and/or planned knee surgery during the study
  • Acute index knee trauma within 3 months prior to screening
  • Knee effusion requiring aspiration of the index or contralateral knee within 3 months prior to screening.
  • Contralateral knee pain above limits defined in the protocol
  • Current therapy with any therapy or medical conditions likely to require systemic steroids during the study.
  • Any active or systemic infection including infection of the index knee joint or breakdown or disease of the index knee skin/soft tissues.
  • intercurrent illness, medical condition, non-knee pain, or medical history that would jeopardize patient safety, limit participation, or compromise interpretation of data derived from the patient
  • Active alcohol or substance use disorder, or any other reason that would make it unlikely that the patient will comply with study procedures
  • Females who are pregnant or lactating
  • Participation in another clinical trial within the 30 days (or 5 half-lives of the compound, whichever is longer) before screening.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
594 participants (actual)

Study arms

  • Experimental
    ASA

    Participants receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline)

    Biological: Amniotic Suspension Allograft

  • Placebo comparator
    Placebo

    Participants receive a single IA injection of 4 mL of normal saline

    Drug: Placebo

Interventions

  • BiologicalAmniotic Suspension Allograft

    This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.

  • DrugPlacebo

    Matching placebo is 0.9% normal saline: 4 mL to be injected IA.

06

What researchers measure

Primary outcomes

  1. The difference in change from baseline in WOMAC Pain scale at 6 months between ASA- and placebo-treated patients

    The WOMAC is widely used in the evaluation of hip and knee OA. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales: pain, stiffness, and physical function. The WOMAC measure has been used in clinical trials to evaluate the efficacy of surgical treatments, medicinal and biological products, devices, and physical therapies.

    Time frame: Baseline to Week 26

Secondary outcomes

  1. The difference between changes from baseline for ASA- and placebo- treated patients in WOMAC Function at 6 months

    The WOMAC is widely used in the evaluation of hip and knee OA. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales: pain, stiffness, and physical function. The WOMAC measure has been used in clinical trials to evaluate the efficacy of surgical treatments, medicinal and biological products, devices, and physical therapies.

    Time frame: Baseline to Week 26

  2. The difference between changes from baseline for ASA- and placebo-treated patients in the OMERACT-OARSI responder rate at 6 months

    The OMERACT-OARSI core domain set for clinical trials in hip and/or knee osteoarthritis responder criteria will be used to assess whether a patient is a responder or not.

    Time frame: Baseline to Week 26

  3. The difference between changes from baseline for ASA- and placebo-treated patients in WOMAC Pain at 3 months

    The WOMAC is widely used in the evaluation of hip and knee OA. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales: pain, stiffness, and physical function. The WOMAC measure has been used in clinical trials to evaluate the efficacy of surgical treatments, medicinal and biological products, devices, and physical therapies.

    Time frame: Baseline to Week 12

07

Study locations

41 sites
  • Central Research Associates, Inc.
    Birmingham, Alabama 35205, United States
  • Alabama Clinical Therapeutics, LLC
    Birmingham, Alabama 35235, United States
  • Fiel Family & Sports Medicine
    Tempe, Arizona 85283, United States
  • Horizon Clinical Research
    La Mesa, California 91942, United States
  • Neurovations Research
    Napa, California 94558, United States
  • Infinity Clinical Research
    Norco, California 92860, United States
  • Dream Team Clinical Research
    Pomona, California 91767, United States
  • Stanford Medicine
    Redwood City, California 94063, United States
  • TriWest Research Associates
    San Diego, California 92108, United States
  • AppleMed Research Group, LLC.
    Miami, Florida 33126, United States
  • Gulfcoast Research Institute
    Sarasota, Florida 34232, United States
  • CenExcel/ACMR
    Atlanta, Georgia 30331, United States
  • Vista Clinical Research
    Newnan, Georgia 30265, United States
  • Chicago Clinical Research Institute Inc.
    Chicago, Illinois 60607, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Advanced Quality Medical Research, Inc
    Orland Park, Illinois 60462, United States
  • MediSphere Medical Research Center
    Evansville, Indiana 47714, United States
  • Sinai Hospital
    Baltimore, Maryland 21215, United States
  • Klein & Associates M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • Skylight Health Research
    Burlington, Massachusetts 01803, United States
  • Oakland Medical Research
    Troy, Michigan 48085, United States
  • Sundance Clinical Research
    St Louis, Missouri 63141, United States
  • Physician Research Collaboriation, LLC
    Lincoln, Nebraska 68516, United States
  • Quality Clinical Research
    Omaha, Nebraska 68114, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Northwell Health
    New York, New York 10065, United States
  • Upstate Clinical Research Associates, LLC
    Williamsville, New York 14221, United States
  • West Clinical Research
    Morehead City, North Carolina 28557, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43202, United States
  • Conrad Clinical Research
    Edmond, Oklahoma 73013, United States
  • Tekton Research
    Yukon, Oklahoma 73099, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Clinical Trials of South Carolina
    Charleston, South Carolina 29406, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • Cedar Health Research, LLC
    Burleson, Texas 76028, United States
  • ClinRXResearch INC
    Carrollton, Texas 75007, United States
  • Zenos Clinical Research
    Dallas, Texas 75230, United States
  • JBR Clinical Research
    Salt Lake City, Utah 84107, United States
  • Spectrum Medical, Inc.
    Danville, Virginia 24541, United States
  • Spokane Joint Replacement Center
    Spokane, Washington 99218, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Aug 2025, 23 months.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's 23 months is above that.

Counting every sponsor, half of 100 studies reached it within 21 months; a quarter within 15 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Aug 21, 2023
StartActual
Sep 6, 2023
Primary completionActual
Aug 15, 2025
CompletionActual
Nov 30, 2025
Results delay requested
Apr 17, 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06000410
Lead sponsor
Organogenesis
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Sep 6, 2023
Primary completion
Aug 15, 2025
Completion
Nov 30, 2025
Last update
Apr 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion